| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
N-trans-p-coumaroyloctopamine's mechanism of action is not fully defined, but it is studied for its antioxidant, cytotoxic, and anti-diabetic properties. As a phenylpropanoid amide, it likely exerts its effects through the modulation of oxidative stress and cellular signaling pathways. It may interact with various cellular targets involved in these processes.
|
|---|---|
| ln Vitro |
In vitro, N-trans-p-coumaroyloctopamine has been studied for its antioxidant, cytotoxic, and anti-diabetic properties. Its antioxidant activity is likely due to the presence of the phenolic hydroxyl group, which can scavenge free radicals. Its cytotoxic effects have been studied in cancer cell lines, and its anti-diabetic potential is being explored.
|
| ln Vivo |
In vivo, the therapeutic potential of N-trans-p-coumaroyloctopamine is being explored. Its antioxidant and anti-diabetic properties suggest potential applications in metabolic diseases. However, specific in vivo data are limited.
|
| Enzyme Assay |
In vitro non-cell assays for N-trans-p-coumaroyloctopamine typically involve measuring its antioxidant activity using DPPH, ABTS, or FRAP assays. Its ability to inhibit enzymes relevant to diabetes, such as α-glucosidase or α-amylase, can be measured using chromogenic substrates.
|
| Cell Assay |
In vitro cell-based assays for N-trans-p-coumaroyloctopamine use cancer cell lines to study its cytotoxic effects via MTT or similar assays. For anti-diabetic studies, its effect on glucose uptake in adipocytes or muscle cells can be measured. Its anti-inflammatory activity can be assessed by measuring cytokine production in LPS-stimulated macrophages.
|
| Animal Protocol |
In vivo animal studies for N-trans-p-coumaroyloctopamine are limited. Standard protocols for studying anti-diabetic effects would involve oral glucose tolerance tests (OGTT) in diabetic rodent models. Its antioxidant effects could be studied in models of oxidative stress.
|
| ADME/Pharmacokinetics |
N-trans-p-coumaroyloctopamine has a molecular weight of 299.32 g/mol and a molecular formula of C₁₇H₁₇NO₄. It is a naturally occurring compound with a purity of 99%. It is soluble in organic solvents. Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of N-trans-p-coumaroyloctopamine has not been fully characterized. As a natural compound, it is generally considered to have low toxicity. However, comprehensive toxicological studies are needed.
|
| References | |
| Additional Infomation |
N-trans-p-coumaroyl octylamine is a member of the styrene class of compounds.
N-trans-p-coumaroyloctopamine is a naturally occurring phenylpropanoid amide found in eggplant and other plants. It has been studied for its antioxidant, cytotoxic, and anti-diabetic properties. It is a valuable research tool for studying plant-derived bioactive compounds. Not approved for clinical use. |
| Molecular Formula |
C17H17NO4
|
|---|---|
| Molecular Weight |
299.3212
|
| Exact Mass |
299.115
|
| CAS # |
66648-45-1
|
| PubChem CID |
23874492
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
638.9±55.0 °C at 760 mmHg
|
| Melting Point |
214 - 215 °C
|
| Flash Point |
340.2±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.677
|
| LogP |
1.26
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
369
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1/C=C/C(=O)NCC(C2=CC=C(C=C2)O)O)O
|
| InChi Key |
VATOSFCFMOPAHX-XCVCLJGOSA-N
|
| InChi Code |
InChI=1S/C17H17NO4/c19-14-6-1-12(2-7-14)3-10-17(22)18-11-16(21)13-4-8-15(20)9-5-13/h1-10,16,19-21H,11H2,(H,18,22)/b10-3+
|
| Chemical Name |
(E)-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-(4-hydroxyphenyl)prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~278.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL | |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
